{"id":"NCT01632904","sponsor":"Incyte Corporation","briefTitle":"Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study","officialTitle":"Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2014-03","completion":"2016-05","firstPosted":"2012-07-03","resultsPosted":"2015-04-07","lastUpdate":"2017-11-14"},"enrollment":110,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Polycythemia Vera"],"interventions":[{"type":"DRUG","name":"Ruxolitinib","otherNames":[]},{"type":"DRUG","name":"Hydroxyurea (HU)","otherNames":[]},{"type":"DRUG","name":"HU-placebo","otherNames":[]},{"type":"DRUG","name":"Ruxolitinib-placebo","otherNames":[]}],"arms":[{"label":"ruxolitinib and hydroxyurea (HU)-placebo","type":"EXPERIMENTAL"},{"label":"HU and ruxolitinib-placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically meaningful symptom improvement (ie, total symptom score reduction of ≥ 50% reduction) at Week 16 compared to Baseline. The study is also designed to demonstrate that these responses are durable with continued treatment.","primaryOutcome":{"measure":"Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary","timeFrame":"From Baseline to Week 16","effectByArm":[{"arm":"Ruxolitinib","deltaMin":43.4,"sd":null},{"arm":"Hydroxyurea","deltaMin":29.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.139"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":70,"countries":["United States","Belgium","Germany","Ireland","Italy","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":54},"commonTop":["Fatigue","Diarrhea","Anemia","Headache","Dizziness"]}}